OncLive Staff

Articles

OncLive December Recap: FDA Approval Highlights

December 30th 2023

In case you missed it, below are some of the drugs that were approved by the FDA in the month of December.

Jabbour Reports Top Takeaways From ASH 2023 of Olverembatinib in CML and ALL

December 28th 2023

Dr Jabbour discusses the activity and the utilization of olverembatinib in chronic myeloid leukemia and expanded upon the role that TKIs can play in the management of malignancies beyond chronic myeloid leukemia and acute lymphoblastic leukemia.

Eskander Emphasizes the Importance of Inclusivity and Accessibility in Oncology Clinical Trials

December 25th 2023

Dr Eskander discusses the impact of social determinants of health on cancer clinical trial participation; effective strategies for considering and engaging diverse communities in the clinical trial process; and how community partnerships can be strengthened to eliminate these financial and logistical barriers.

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

December 21st 2023

Drs Lunning and Mehta-Shah highlight challenges that arise when diagnosing patients with peripheral T-cell lymphoma and how molecular testing results influence induction and consolidation treatment approaches for patients with ALK-negative anaplastic large cell lymphoma.

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

December 18th 2023

Drs Simeone and Fakih discuss the main objective and design of the observational BASECAMP-1 study and how it functions alongside the EVEREST-1 study, which is evaluating the autologous CAR T-cell therapy A2B530 in patients with CEA-expressing solid tumors that have lost HLA-A*02 expression.

Camidge and Gerber Emphasize the Importance of Face-to-Face Patient Connections

December 14th 2023

Drs Camidge and Gerber highlight the ways that a liberal arts education can lay the foundation for a successful career in academic medicine; the importance and various forms of mentorship; and how clinical investigators can use their experiences and data to drive national policy changes.

Donington and Stiles Describe the Surgical Implications of Lung Cancer Treatment Evolutions

December 11th 2023

Drs Donington and Stiles discuss how the findings from the ADAURA trial with adjuvant osimertinib have changed thoracic surgery expectations, the potential surgical implications of the ALINA trial with adjuvant alectinib, and the importance of early-stage molecular testing in lung cancer.

Abdou Spotlights Factors Influencing ADC Treatment Selection in Breast Cancer

December 7th 2023

Dr Abdou discusses how characteristics of patients with breast cancer impact ADC treatment selection and highlights some of the topline takeaways from breast cancer treatment to come out of the 2023 ASCO Annual Meeting.

FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

December 4th 2023

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how this regulatory decision increases the importance of multidisciplinary collaboration.

Lunning and Jacobson Dissect the Role of CAR T-Cell Therapy in Follicular Lymphoma

November 30th 2023

Drs Lunning and Jacobson discuss the characteristics of follicular lymphoma that may prompt aggressive treatment, the potential optimal role of CAR T-cell therapy in the third line and beyond, and how the toxicity profiles of different CAR T-cell products compare with each other.

Camidge and McVeigh Highlight the Role of the Clinical Geneticist Across Cancer Care and Research

November 27th 2023

Drs Camidge and McVeigh highlight the evolution of the clinical genetics field over time, the process of identifying pathogenic genetic variants, the difficulties of explaining genetic testing results to patients, and more.

Dumbrava Details Ongoing Research With PC14586 in p53 Y220C–Mutated Advanced Solid Tumors

November 23rd 2023

Dr Dumbrava discusses the rationale and design of the PYNNACLE trial; phase 1 efficacy and safety findings with PC14586 in patients with p53 Y220C–mutated advanced solid tumors; and the next steps for this research.

FDA Approval Insights: Ivosidenib in R/R IDH1+ Myelodysplastic Syndrome

November 20th 2023

Dr DiNardo discusses the the FDA approval of ivosidenib for patients with relapsed/refractory IDH1-mutant myelodysplastic syndromes, the unique mechanism of action of ivosidenib, and key efficacy and safety findings from the AG120-C-001 trial.

Halmos Highlights Evaluation of the EGFR Inhibitor BDTX-1535 in NSCLC

November 16th 2023

Dr Halmos discusses the ongoing investigation of the potent, selective, and irreversible EGFR inhibitor BDTX-1535 in patients with non–small cell lung cancer.

Feigin Discusses the Association Between Benzodiazepines and Pancreatic Cancer Outcomes

November 13th 2023

Dr Feigin discusses findings from a study on the varying effects of the benzodiazepines lorazepam and alprazolam on progression-free survival outcomes for patients with pancreatic cancer.

Khouri Highlights the Ongoing AFFIRM-AL Trial in AL Amyloidosis

November 9th 2023

Dr Khouri discusses unmet needs in AL amyloidosis, the potential for birtamimab to become a new frontline standard of care, and the importance of confirming earlier post-hoc results from the VITAL trial in the AFFIRM-AL trial in patients with Mayo stage IV AL amyloidosis with cardiac involvement.

FDA Approval Insights: Adjuvant Nivolumab in Completely Resected Stage IIB/C Melanoma

November 6th 2023

Dr Weber discusses the FDA approval of adjuvant nivolumab for patients with completely resected stage IIB/C melanoma, key efficacy data from the CheckMate76K trial, and potential future directions for PD-1 inhibitor–based combinations in the melanoma treatment paradigm.

Camidge and Garon Unpack Key Updates From the 2023 IASLC World Conference on Lung Cancer

November 2nd 2023

In this episode of How This Is Building Me, Drs Camidge and Garon discuss the differences in lung cancer management and drug advancement between the United States and Asia and highlight other topline takeaways from the 2023 WCLC.

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

October 30th 2023

Drs Lunning and Nastoupil discuss the ins and outs of diagnostic workups for patients with follicular lymphoma; how to discern which patients may benefit most from standard chemotherapy vs clinical trial regimens in the frontline setting; and ongoing follicular lymphoma research that may alter the treatment paradigm.

Naumann Discusses Notable Research Efforts in Endometrial Cancer

October 26th 2023

Dr Naumann discusses the role of frontline maintenance therapy for patients with endometrial cancer; which patients are likely to benefit from the RUBY and NRG-GY018 trial regimens; and ongoing research that may elucidate optimal treatments for patients with recurrent, mismatch repair–deficient disease.